• Users Online: 88
  • Home
  • Print this page
  • Email this page
Home About us Arab Society Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2017  |  Volume : 12  |  Issue : 1  |  Page : 13-18

Immunohistochemical expression of HER-2/neu receptors in gastric carcinoma

1 Department of Pathology, Cairo University, Giza, Egypt
2 Department of Pathology, Medical Division, National Research Centre, Giza, Egypt

Correspondence Address:
Rofanda M Bakeer
Department of Pathology, Medical Division, National Research Centre, El Bohoth Street, Dokki, Giza, 12311
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jasmr.jasmr_4_17

Rights and Permissions

Background/aim Gastric carcinoma is the fourth most commonly diagnosed cancer and the second most common cause of cancer-related death. It is associated with patient morbidity and mortality worldwide. Adenocarcinomas represent 90% of gastric carcinoma cases and are classified into intestinal and diffuse types. Human epidermal growth factor receptor 2 (HER-2)/neu overexpression is a predictor of poor prognosis. This study aimed to evaluate HER-2/neu expression in gastric carcinomas and to correlate its expression with clinicopathological parameters and other prognostic factors. Patients and methods Forty-five cases of primary gastric carcinoma were included in this study. Thirty-two cases were of intestinal type and 13 cases were of the diffuse type. All specimens were formalin fixed, routinely processed, stained with hematoxylin and eosin, and immunohistochemically stained with HER-2/neu. Results Overexpression of HER-2/neu was detected in five out of 30 (11.1%) gastric carcinomas. There was a nonsignificant difference (P>0.05) in different histologic types. Also HER-2/neu expression showed a nonsignificant correlation with both histologic grade and tumor stage. Conclusion Our results revealed a limited effect of HER-2/neu on the biologic behavior of gastric carcinoma. However, further study with a larger sample size is recommended to clarify the therapeutic role of trastuzumab (Herceptin) in gastric carcinoma patients expressing HER-2/neu.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded224    
    Comments [Add]    

Recommend this journal